Moneycontrol PRO
HomeNewsBusinessEarningsCipla Q2 net profit rises 3.7% to Rs 1,353 crore

Cipla Q2 net profit rises 3.7% to Rs 1,353 crore

Achin Gupta, Global Chief Operating Officer, has been elevated and appointed as the Managing Director & Global Chief Executive Officer with effect from April 1, 2026, for a term of five years up to March 31, 2031.

October 30, 2025 / 17:58 IST
Cipla Q2 results

Pharma major Cipla Ltd on Thursday reported a 3.7 per cent rise in consolidated net profit at Rs 1,353.37 crore for the second quarter ended September 30, 2025.

The company, which had posted a consolidated net profit of Rs 1,305.01 crore in the second quarter of the last fiscal year, said its Managing Director & Global CEO, Umang Vohra, has decided not to seek re-appointment upon completion of his current term on March 31, 2026, Cipla Ltd said in a regulatory filing.

Subsequently, Achin Gupta, Global Chief Operating Officer, has been elevated and appointed as the Managing Director & Global Chief Executive Officer with effect from April 1, 2026, for a term of five years up to March 31, 2031.

Cipla said its consolidated total revenue from operations in the second quarter stood at Rs 7,589.44 crore, as against Rs 7,051.02 crore in the year-ago period.

Total expenses in the quarter under review were higher at Rs 6,004.86 crore, as compared to Rs 5,452.57 crore in the corresponding period last fiscal, the company said.

In the second quarter, the pharmaceuticals segment recorded revenue of Rs 7,291.43 crore, up from Rs 6,775.56 crore in the same period a year ago.

New ventures registered revenue of Rs 350.68 crore, as against Rs 319.6 crore, the filing said.

"In Q2FY26, we delivered our highest-ever quarterly revenue of Rs 7,589 crore, with a robust EBITDA margin of 25 per cent. What makes this performance commendable is the breadth and balance of our growth, driven by contributions across all our focused markets," Vohra said.

The company's 'One-India business' grew by 7 per cent year-on-year, while trade generics recorded double-digit growth, and the anchor brands of the consumer health business maintained a leadership position, he noted.

"With a positive traction in our differentiated assets, the US business posted a revenue of USD 233 million during the quarter," he added.

On 'One Africa', Vohra said, "We achieved a healthy growth of 5 per cent YoY in USD terms. Emerging Markets and Europe delivered a solid revenue growth of 15 per cent YoY in USD terms on the back of a deep market focus strategy." Going ahead, he said, "The focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front."

Also read: Our LIVE blog on Q2 updates

PTI
first published: Oct 30, 2025 05:55 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347